Skip to main content
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction
- PR Newswire - PRF - Mon Oct 26, 9:00AM CDT
PR Newswire - PRF - CMTX
Mon Oct 26, 9:00AM CDT
, /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for the Abre™ venous self-expanding stent system. This device is indicated for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow obstruction, also known as deep venous obstruction.
Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction
- PR Newswire - Mon Oct 26, 9:00AM CDT
PR Newswire - PRNW
Mon Oct 26, 9:00AM CDT
DUBLIN , Oct. 26, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for the Abre™ venous self-expanding stent system. This device is indicated for use in the iliofemoral veins in patients with symptomatic iliofemoral venous outflow obstruction, also known as deep venous obstruction.
Titan Medical Announces Achievement of $10 Million Technical Milestone Under Medtronic Development and License Agreement
- BusinessWire - Mon Oct 26, 6:30AM CDT
BusinessWire - CMTX
Mon Oct 26, 6:30AM CDT
Titan Medical Inc. ("Titan" or the "Company") (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has completed the first technical milestone under the development and license agreement with Medtronic plc ("Medtronic") (NYSE: MDT), and is due to receive a U.S. $10 million payment.
Medtronic Plc Rises 2.97% on Heavy Volume: Watch For Potential Pullback
- Comtex SmarTrend(R) - Fri Oct 23, 12:00PM CDT
Comtex SmarTrend(R) - CMTX
Fri Oct 23, 12:00PM CDT
Medtronic Plc (NYSE:MDT) traded in a range yesterday that spanned from a low of $111.31 to a high of $112.48. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $112.20 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
US Heart Valve Repair and Replacement Market Size | 2020, Growth Strategies, Opportunity, Challenges, Rising Trends and Revenue Analysis 2025
- Heraldkeepers - Fri Oct 23, 7:51AM CDT
Heraldkeepers - CMTX
Fri Oct 23, 7:51AM CDT
The delivers a succinct analysis on industry size, regional growth and revenue forecasts for the upcoming years. The report further sheds light on significant challenges and latest growth strategies adopted by manufacturers who are a part of the competitive spectrum of this
Prosthetic Heart Valve/ Artificial Heart Valve Market Research: Growth Opportunities Regions, Types, Applications, Detail Research for Business Development Insights [2020-2025]
- Heraldkeepers - Fri Oct 23, 5:47AM CDT
Heraldkeepers - CMTX
Fri Oct 23, 5:47AM CDT
The Prosthetic Heart Valve/ Artificial Heart Valve Market is expected to exceed more than US$ 9 Billion by 2024 at a CAGR of 13% in the given forecast period.
Worldwide Surgical Robots Industry to 2025 - Featuring Stryker, Medtronic and Intuitive Surgical Among Others
- PR Newswire - PRF - Wed Oct 21, 10:30AM CDT
PR Newswire - PRF - CMTX
Wed Oct 21, 10:30AM CDT
, /PRNewswire/ -- The report has been added to offering.
Patients Report Superior, Sustained and Profound Back Pain Relief at 12 Months with DTM™ Spinal Cord Stimulation Therapy Using the Medtronic Intellis™ Platform
- PR Newswire - PRF - Tue Oct 20, 6:30AM CDT
PR Newswire - PRF - CMTX
Tue Oct 20, 6:30AM CDT
, /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced statistically significant 12-month results from a large, multicenter randomized controlled trial (RCT) that further validate the superiority of DTM™ Spinal Cord Stimulation (SCS) in providing back pain relief, compared with conventional SCS therapy, using the Medtronic Intellis™ platform.
Patients Report Superior, Sustained and Profound Back Pain Relief at 12 Months with DTM™ Spinal Cord Stimulation Therapy Using the Medtronic Intellis™ Platform
- PR Newswire - Tue Oct 20, 6:30AM CDT
PR Newswire - PRNW
Tue Oct 20, 6:30AM CDT
DUBLIN , Oct. 20, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced statistically significant 12-month results from a large, multicenter randomized controlled trial (RCT) that further validate the superiority of DTM™ Spinal Cord Stimulation (SCS) in providing back pain relief, compared with conventional SCS therapy, using the Medtronic Intellis™ platform.
Orthopedic Devices Market to Rise at 6.6% CAGR and Reach USD 68.51 Billion by by 2027; Increasing Prevalence of Musculoskeletal Disorders will Emerge in Favor of Market Growth, says Fortune Business Insights(TM)
- GlobeNewswire - Mon Oct 19, 7:34AM CDT
GlobeNewswire - CMTX
Mon Oct 19, 7:34AM CDT
The global orthopedic devices market size is projected to reach USD 68.51 billion by the end of 2027. The increasing investments in product R&D will emerge in favor of market growth. According to a report published by Fortune Business Insights, titled "Orthopedic Devices Market Size, Share & COVID-19 Impact Analysis, By Type (Joint Reconstruction Devices, Spinal Devices, Trauma Devices, Orthobiologic Devices, Arthroscopy Devices, and Others), By End User (Hospitals, Orthopedic Clinic, Ambulatory Surgical Centers, and Others), and Regional Forecast, 2020-2027," the market was worth USD 53.44 billion and will exhibit a CAGR of 6.6% during the forecast period, 2020-2027.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies